In a single-center, retrospective review of incidences of PRES in patients with cancer, 6 of the 31 identified patients had received bevacizumab and 2 had been treated with both bevacizumab and sunitinib, a multikinase inhibitor with anti-VEGF activity [28]. The gene discussed is VEGFA; the disease is Posterior Leukoencephalopathy Syndrome.